Patents by Inventor Paul T. Wingfield

Paul T. Wingfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11827669
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Hepatitis B Virus infection in mammals, and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: November 28, 2023
    Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Paul T. Wingfield, Norman R. Watts, Alasdair C Steven
  • Publication number: 20210380668
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Hepatitis B Virus infection in mammals, and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: July 19, 2018
    Publication date: December 9, 2021
    Inventors: Paul T. WINGFIELD, Norman R. WATTS, Alasdair C. STEVEN
  • Publication number: 20120201811
    Abstract: Described herein is the identification, though phage display, of a chimeric rabbit/human anti-Rev Fab (SJS-R1) that readily solubilized polymeric HIV-1 Rev. The Fab binds with very high affinity to a conformational epitope in the N-terminal half of HIV-1 Rev. The corresponding single chain antibody (scFv) was also prepared and characterized. Methods of making and using SJS-R1 Fab and SJS-R1 scFv, and antibodies and antibody fragments that share at least one CDR with SJS-R1 Fab, are provided. Specific described methods include methods of preventing or reversing polymerization of HIV Rev, methods of preventing or inhibiting replication of a lentivirus in a cell, methods of reducing infectivity of replication of a lentivirus, inhibiting Rev function in a cell infected with a lentivirus, and methods of treating a disease or symptom associated with Rev expression in an animal.
    Type: Application
    Filed: February 3, 2012
    Publication date: August 9, 2012
    Inventors: Stephen J. Stahl, Norman R. Watts, Paul T. Wingfield, Christoph Rader, Alasdair C. Steven
  • Patent number: 7605127
    Abstract: The present invention relates to a novel truncated form of heptocyte growth factor (HGF) which specifically antagonizes the activity of HGF and to a novel truncated form of HGF that is a partial HGF agonist. In particular, the present invention relates to the purification, molecular cloning, recombinant expression of the truncated HGF variants and related pharmaceutical compositions. The present invention further relates to the utilization of the small HGF variants to either inhibit HGF mitogenesis or stimulate HGF mitogenesis in cells expressing the receptor for HGF.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: October 20, 2009
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Andrew M. L. Chan, Jeffrey S. Rubin, Donald P. Bottaro, Stuart A. Aaronson, Stephen J. Stahl, Paul T. Wingfield, Vittoria Cioce
  • Patent number: 7041441
    Abstract: Disclosed is a phage display system in which the molecules to be displayed (i.e., molecules of interest) are bound to dispensable capsid polypeptides such as SOC (small outer capsid) and HOC (highly antigenic outer capsid) polypeptides that are, in turn, bound to a surface lattice protein, such as those on the surface of a virion or polyhead. Also disclosed are methods of displaying a molecule of interest, methods of immunizing a patient by administering a displayed antigen, and methods of treating a patient who has a disorder associated with aberrent expression or activity of a biological molecule. In the latter instance, the method includes administering a displayed polypeptide, such as an immunoglobulin molecule or an enzyme, that is capable of specifically interacting with the aberrent biological molecule.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: May 9, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Alasdair C. Steven, Paul T. Wingfield, Lindsay W. Black, Zhaojun Ren
  • Publication number: 20030124671
    Abstract: The present invention relates to a novel truncated forms of hepatocyte growth factor (HGF) which specifically antagonizes the activity of HGF and to a novel truncated form of HGF that is a partial HGF agonist. In particular, the present invention relates to the purification, molecular cloning, recombinant expression of the truncated HGF variants and related pharmaceutical compositions.
    Type: Application
    Filed: October 30, 2002
    Publication date: July 3, 2003
    Inventors: Andrew M.L. Chan, Jeffrey S. Rubin, Donald P. Bottaro, Stuart A. Aaronson, Stephen J. Stahl, Paul T. Wingfield, Vittoria Cioce